← 홈

난소암

353개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 353개
ADCBiologicstaleGlaxoSmithKlinePhase 2

PI3K-beta Inhibitor GSK2636771 (PI3K-beta Inhibitor GSK2636771)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 9%임상시험 8상태 RECRUITING
ADCBiologicGenmabPhase 3

Rina-S (Rina-S)

High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 8상태 RECRUITING
CGTBiologicstaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 77.3%임상시험 7상태 RECRUITING
ADCBiologicstaleCanadian Myeloma Research GroupPhase 2

GSK2857916 with Pomalidomide and Dexamethasone (GSK2857916 with Pomalidomide and Dexamethasone)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 7상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Raludotatug deruxtecan (Raludotatug deruxtecan)

Ovarian Cancer Recurrent · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 7상태 RECRUITING
AntibodystaleARCAGYPhase 2

Ubamatamab (Ubamatamab)

Ovarian Cancer · Recurrent Ovarian Cancer

#RecurrentOvarianCancer#Antibody#Phase2#항체#면역항체+3
임상시험 7상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 1

DS-6000a (DS-6000a)

Renal Cell Carcinoma; Ovarian Tumor · Renal Cell Carcinoma

#RenalCellCarcinoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 3

Mirvetuximab soravtansine plus Bevacizumab (Mirvetuximab soravtansine plus Bevacizumab)

Ovarian Cancer; Peritoneal Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 100%임상시험 6상태 RECRUITING
ADCBiologicGlaxoSmithKlinerezetecanPhase 3

Mocertatug rezetecan (Mocertatug rezetecan)

Ovarian Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 6상태 RECRUITING
ADCBiologicstaleTasly Pharmaceutical Group Co.,…Phase 2

STRO-002 (STRO-002)

Neoplasm Malignant · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 6상태 DISCONTINUED
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting CD7 chimeric antigen receptor (T cell injection targeting CD7 chimeric antigen receptor)

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 6상태 ACTIVE
ADCBiologicstaleAstraZenecaPhase 2

AZD9574 (AZD9574)

Advanced Solid Malignancies · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 5상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

GSK3174998 (GSK3174998)

Neoplasms · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 11.1%임상시험 5상태 RECRUITING
ADCBiologicstaleNational Cancer Institute (NCI)Phase 2

Larotrectinib Sulfate (Larotrectinib Sulfate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 60%임상시험 5상태 RECRUITING
ADCBiologicstaleSanofiPhase 2

Pegenzileukin (Pegenzileukin)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 92.9%임상시험 5상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

cBR96-Doxorubicin Immunoconjugate (SGN-15, SGN-15 (cBR96-Doxorubicin Immunoconjugate))

Ovarian Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 5상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED

6 / 18 페이지

← 이전다음 →